Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Mr. Edward J. Hejlek Esq., J.D.

Executive Vice President of Intellectual Property

Mr. Geoffrey M. Parker

Chief Operating Officer, Chief Financial Officer & Executive Vice President

Mr. Robert L. McKague J.D.

Executive Vice President, Company Sec., Gen. Counsel & Chief Compliance Officer

Jackie  Cossmon

Vice President of Investor Relations & Communications

Dr. Dawn  Parsell Ph.D.

Executive Vice President of Clinical Devel.

Dr. Gerrit  Klaerner Ph.D.

Founder, Pres, Chief Executive Officer & Executive Director

Ms. Annie  Yoshiyama

Vice President of Fin. & Chief Accounting Officer

Biotechnológia

Tricida, Inc.

Tricida, Inc. Vezetői struktúra

Vezetői információk